| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | Form 4 |
| 13 Nov 2026 |
Form 4: Pisano Wayne, Director
Bought 10,000 shares ($16.4K) |
| 13 Nov 2026 |
Form 4: Durso Jerome Benedict, Director
Bought 30,700 shares ($49.7K) |
| 13 Nov 2026 | Form 4 |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Global PERFORMA Phase 3 trial in MASH progressing as planned |
| 10 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 |
Form 4: Greenleaf Peter, Director
Granted 160,000 Stock Options (option to buy) |
| 04 Nov 2026 |
Form 3: Greenleaf Peter, Director
No securities owned |
| 04 Nov 2026 |
Form 4: Howarth Alex G., Director
Granted 160,000 Stock Options (option to buy) |
| 04 Nov 2026 |
Form 3: Howarth Alex G., Director
No securities owned |
| 29 Oct 2026 |
8-K: Creation of a Direct Financial Obligation
On October 27, 2026, Altimmune, Inc. (the “Company”), has drawn $10.0 million in an aggregate principal amount (“Tranche Three”) from its $125.0 million Loan and Security Agreement, dated as of May 13, 2025 (as amended by the Amendment t... |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution |
| 05 Oct 2026 |
Form 4: Arbet-Engels Christophe, Chief Medical Officer
Received 37,500 shares by exercise or conversion · Gave up 12,679 shares to cover exercise price or tax ($35K) |
| 05 Oct 2026 |
Form 4: Weaver Gregory L, Chief Financial Officer
Received 14,475 shares by exercise or conversion · Gave up 4,379 shares to cover exercise price or tax ($12.1K) |
| 02 Oct 2026 |
Form 4: Menziuso Richard Thomas, Principal Accounting Officer
Granted 84,546 Stock Options (option to buy) · Granted 36,234 Restricted Stock Units |
| 02 Oct 2026 |
Form 3: Menziuso Richard Thomas, Principal Accounting Officer
No securities owned |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2... |
| 17 Sep 2026 |
Form 4: Richardson Linda M, Chief Commercial Officer
Received 24,000 shares by exercise or conversion · Gave up 6,826 shares to cover exercise price or tax ($22.1K) |
Loading...